BCAL Diagnostics Limited (ASX:BDX)

Market Cap	22.69M
Revenue (ttm)	2.62M
Net Income (ttm)	-7.99M
Shares Out	365.97M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,009
Average Volume	85,443
Open	0.0610
Previous Close	0.0620
Day's Range	0.0610 - 0.0610
52-Week Range	0.0560 - 0.1400
Beta	0.61
RSI	43.24
Earnings Date	Aug 29, 2025

About ANSYS

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BDX

Financial Performance

In 2024, BCAL Diagnostics's revenue was 3.10 million, an increase of 8.60% compared to the previous year's 2.85 million. Losses were -6.40 million, 26.4% more than in 2023.